联系我们Contact us
1. 基本信息
品系(xi)名称 NOD. Prkdcscid Il2rgtm1 Vst Tg(Csf1p -IL3)Vst/Vst
常用名 hIL-3 NPG /Vst; hIL-3 NPG
背景 NOD-scid/NcrCrl
毛色 白(bai)色
品(pin)系建立：
采用转基因的方法，构建(jian)pCDNA3.1-Csf1p-IL3载体，将线性化Csf1p-IL3表达序列注射到NPG小鼠的原核中，在获得的后代中筛选到合(he)适表达量的阳性小鼠。
在隔(ge)离器中，按照(zhao)近交(jiao)的方式扩繁建立(li)商品化的hIL-3 NPG小鼠品系。
2. 表型(xing)
在(zai)(zai)NPG小(xiao)鼠(shu)中表达(da)人(ren)(ren)的(de)hIL-3细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)因(yin)子。白细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)介素3刺(ci)激多能造血干细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)分化(hua)为髓系祖细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)。可(ke)以(yi)与(yu)表达(da)人(ren)(ren)GM-CSF、M-CSF细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)因(yin)子的(de)NPG小(xiao)鼠(shu)一起(qi)，在(zai)(zai)移植人(ren)(ren)CD34+造血干细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)6-8周后，于外周血、骨髓、胸(xiong)腺和(he)脾脏以(yi)及包括肺和(he)肝在(zai)(zai)内(nei)的(de)非淋(lin)巴组织中，形成稳(wen)定广泛的(de)髓系和(he)淋(lin)巴系细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)分化(hua)。在(zai)(zai)血液和(he)组织中，可(ke)检测到粒(li)细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)分化(hua)（嗜碱性(xing)粒(li)细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)、中性(xing)粒(li)细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)和(he)肥大细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)），抗原呈递细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)分化(hua)（树突状细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)和(he)巨噬细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)）和(he)调节性(xing)T细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)群体等。表达(da)人(ren)(ren)M-CSF、GM-CSF和(he)人(ren)(ren)IL-3细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)因(yin)子与(yu)Hu-NPG人(ren)(ren)源化(hua)小(xiao)鼠(shu)相比，人(ren)(ren)类(lei)造血干细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)（hsc）的(de)整体植入水平更高，分化(hua)细(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)种类(lei)更多。
3. 应用领域
-人源化(hua)和(he)癌症(zheng)治疗
-人体过敏(min)反(fan)应模(mo)型，免疫、造血(xue)移植重建模(mo)型
-再(zai)生医学
-感染性(xing)疾病
-生物(wu)医学
4. 参考文献
（1）Ito R, Takahashi T, Katano I, Kawai K, Kamisako T, Ogura T, Ida-Tanaka M, Suemizu H, Nunomura S, Ra C, Mori A, Aiso S, Ito M. (2013) Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. J Immunol.191(6):2890-9.
（2）Wunderlich M; Chou FS; Link KA; Mizukawa B; Perry RL; Carroll M; Mulloy JC. 2010. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24(10):1785-8.
（3）Billerbeck E; Barry WT; Mu K; Dorner M; Rice CM; Ploss A. 2011. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2R{gamma}null humanized mice. Blood 117(11):3076-86.
（4）Coughlan AM; Harmon C; Whelan S; O'Brien EC; O'Reilly VP; Crotty P; Kelly P; Ryan M; Hickey FB; O'Farrelly C; Little MA. 2016. Myeloid Engraftment in Humanized Mice: Impact of Granulocyte-Colony Stimulating Factor Treatment and Transgenic Mouse Strain. Stem Cells Dev 25(7):530-41.
